IDEXX Laboratories, Inc.

Fundamentals8.0
Price Action4.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Strong Margins
  • High Capital Returns
  • Tight Liquidity

AI
AI Summary

6.0

IDXX remains a high-quality compounder with elite margins and free cash flow, but the key issue is now whether uneven clinic traffic—especially wellness visits—can accelerate enough to justify a rich 40s P/E and 30x+ EV/EBITDA, making valuation compression the main risk unless the stock reclaims the 560 level.

Quality
ValuationRisk
Technicals‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • Strong Margins
  • High Capital Returns
  • Tight Liquidity

IDXX remains a high-quality cash generator with standout margins and returns, but its modest liquidity buffer, rising debt, and premium valuation limit upside and leave little margin for error.

profitable
overvalued

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Failed rebounds
  • Support forming

IDXX fell about 10% over the last month in a steady downtrend with repeated failed rebounds, and the setup stays weak until it can reclaim $560.

downtrend
weakness
Support Level: $528–$533
Resistance Level: $560–$570

Break below $560 and follow-through to the $528 area confirmed weakening momentum

Sentiment & News

6.0

Key News Insights:

  • Valuation Pressure
  • Earnings Beat
  • Raised Outlook

IDXX delivered strong Q1 growth and a raised outlook, but valuation concerns and a muted stock reaction kept sentiment mixed.

IDXX
Earnings

Despite solid fundamentals, the stock may remain under pressure unless growth continues to outpace its premium valuation